WuXi AppTec and New World Development-backed Adagene has raised close to $140m in its initial public offering after having secured $155m in equity financing.

Adagene, a China-based immuno-oncology drug developer backed by pharmaceutical firm WuXi AppTec and conglomerate New World Development, has raised nearly $140m in its initial public offering. The company issued approximately 7.35 million American Depositary Shares (ADSs), representing just over 9.19 million ordinary shares, priced at $19 each. It now trades on the Nasdaq Global Market…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.